Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
APRE compared with PYPD: revenue, margins and what each company keeps, and the suppliers and customers both name
APRE
Aprea Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
PYPD
PolyPid Ltd.
Change
Mkt cap
Revenue
Revenue
vs
Compare
APRE
Aprea Therapeutics, Inc.
vs
PYPD
PolyPid Ltd.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Earnings history
Desk
News
Calendar
Saved
Search
Earnings history
last 4 reports each · paired by recency
Method
›
APRE
1 of 4 reports
Report
implied
realized
× implied
Q2 FY26
—
▲
+3.47%
—
PYPD
No earnings history for PYPD.
= implied
APRE realized, solid
PYPD realized, hatched
One scale, both sides: full bar = 4%
× = |realized| ÷ implied
Source: market data
APRE
Aprea Therapeutics, Inc.
Change
0.50
▲
+3.30%
· post 0.50
Mkt cap
$6.1M
Revenue
$3,337
Q4 FY25
Revenue
$285,759
FY25
PYPD
PolyPid Ltd.
Change
5.35
▼
−0.74%
· post 5.35
Closed
Nov 2 '26
Mkt cap
$88.1M
Revenue
—
Revenue
—
vs
Compare
Closed
Nov 2 '26
APRE
Aprea Therapeutics, Inc.
vs
PYPD
PolyPid Ltd.
0.50
▲
+3.30%
post 0.50
Price
5.35
▼
−0.74%
post 5.35
$6.1M
Mkt cap
$88.1M
Q4 FY25
$3,337
Revenue
—
FY25
$285,759
Revenue
—
Change
Change
APRE
0.50
▲
+3.30%
vs
PYPD
5.35
▼
−0.74%
Closed
Nov 2 '26